Nicox Provides Full Year 2025 Financial Results and Corporate Update

Thu, 30 Apr 2026 01:30:00 -0400

Press Release

Revenue of €16.8 million (€7.9 million in 2024)
Net loss significantly reduced to €2.4 million (€22.4 million in 2024)
NCX 470 U.S. New Drug Application (NDA) submission on track for summer 2026, with associated milestone payment

Regulatory milestones anticipated

Nicox Provides Full Year 2025 Financial Results and Corporate Update

Thu, 30 Apr 2026 01:30:00 -0400

Press Release
Nicox Provides Full Year 2025 Financial Results and Corporate Update

Revenue of €16.8 million (€7.9 million in 2024)
Net loss significantly reduced to €2.4 million (€22.4 million in 2024)
NCX 470 U.S. New Drug Application (NDA) submission on track for summer 2026, with associated milestone payment
Regulatory milestones anticipated

Nicox Provides Full Year 2025 Financial Results and Corporate Update

Thu, 30 Apr 2026 01:30:00 -0400

Press Release
Nicox Provides Full Year 2025 Financial Results and Corporate Update

Revenue of €16.8 million (€7.9 million in 2024)
Net loss significantly reduced to €2.4 million (€22.4 million in 2024)
NCX 470 U.S. New Drug Application (NDA) submission on track for summer 2026, with associated milestone payment
Regulatory milestones anticipated

Nicox Provides Full Year 2025 Financial Results and Corporate Update

Thu, 30 Apr 2026 01:30:00 -0400

Press Release
Nicox Provides Full Year 2025 Financial Results and Corporate Update

Revenue of €16.8 million (€7.9 million in 2024)
Net loss significantly reduced to €2.4 million (€22.4 million in 2024)
NCX 470 U.S. New Drug Application (NDA) submission on track for summer 2026, with associated milestone payment
Regulatory milestones anticipated

Nicox Announces Shareholder Q&A Webpage Available

Tue, 26 Aug 2025 01:30:00 -0400

Press Release
Nicox Announces Shareholder Q&A Webpage Available

August 26, 2025 – release at 7:30 am CET
Sophia Antipolis, France

Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that a new webpage “Q&A” is available on the company’s website, www.nicox.com, including information on the most frequently asked questions for shareholders in

Nicox Announces Shareholder Q&A Webpage Available

Tue, 26 Aug 2025 01:30:00 -0400

Press Release
Nicox Announces Shareholder Q&A Webpage Available

August 26, 2025 – release at 7:30 am CET
Sophia Antipolis, France

Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that a new webpage “Q&A” is available on the company’s website, www.nicox.com, including information on the most frequently asked questions for shareholders in

Nicox Announces Shareholder Q&A Webpage Available

Tue, 26 Aug 2025 01:30:00 -0400

Press Release
Nicox Announces Shareholder Q&A Webpage Available

August 26, 2025 – release at 7:30 am CET
Sophia Antipolis, France

Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that a new webpage “Q&A” is available on the company’s website, www.nicox.com, including information on the most frequently asked questions for shareholders in

Nicox Announces Shareholder Q&A Webpage Available

Tue, 26 Aug 2025 01:30:00 -0400

Press Release
Nicox Announces Shareholder Q&A Webpage Available

August 26, 2025 – release at 7:30 am CET
Sophia Antipolis, France

Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that a new webpage “Q&A” is available on the company’s website, www.nicox.com, including information on the most frequently asked questions for shareholders in

Counter tariff ideas in Broadcast TV- Benchmark

Mon, 07 Apr 2025 08:00:50 -0400

In a new note on Broadcasting Benchmark discussed the directly recession impacted broadcast television sector, and the hard to guess nature of winners and losers with NAB beginning a couple of days ago and the risk of fundamentals deteriorating further.
The analyst commented, “Fundamentally, it looks like it could be a tough year for the entire group. Those forecasting core growth for the year in late February might want that outlook back as things were already softening before the tariffs hit the market. Granted, no one knows how this is all going to play out, but uncertainty is never good for

Counter tariff ideas in Broadcast TV- Benchmark

Mon, 07 Apr 2025 08:00:50 -0400

In a new note on Broadcasting Benchmark discussed the directly recession impacted broadcast television sector, and the hard to guess nature of winners and losers with NAB beginning a couple of days ago and the risk of fundamentals deteriorating further.
The analyst commented, “Fundamentally, it looks like it could be a tough year for the entire group. Those forecasting core growth for the year in late February might want that outlook back as things were already softening before the tariffs hit the market. Granted, no one knows how this is all going to play out, but uncertainty is never good for

Counter tariff ideas in Broadcast TV- Benchmark

Mon, 07 Apr 2025 08:00:50 -0400

In a new note on Broadcasting Benchmark discussed the directly recession impacted broadcast television sector, and the hard to guess nature of winners and losers with NAB beginning a couple of days ago and the risk of fundamentals deteriorating further.
The analyst commented, “Fundamentally, it looks like it could be a tough year for the entire group. Those forecasting core growth for the year in late February might want that outlook back as things were already softening before the tariffs hit the market. Granted, no one knows how this is all going to play out, but uncertainty is never good for

Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial

Wed, 19 Mar 2025 02:30:00 -0400

Press Release
Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial

Results expected in May 2025
Last patient in the U.S. in the ongoing NCX 470 Denali Phase 3 trial has also completed their last visit and results remain on track for Q3 2025
March 19, 2025 –

Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial

Wed, 19 Mar 2025 02:30:00 -0400

Press Release
Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial

Results expected in May 2025
Last patient in the U.S. in the ongoing NCX 470 Denali Phase 3 trial has also completed their last visit and results remain on track for Q3 2025
March 19, 2025 –

Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial

Wed, 19 Mar 2025 02:30:00 -0400

Press Release
Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial

Results expected in May 2025
Last patient in the U.S. in the ongoing NCX 470 Denali Phase 3 trial has also completed their last visit and results remain on track for Q3 2025
March 19, 2025 –

Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial

Wed, 19 Mar 2025 02:30:00 -0400

Press Release
Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial

Results expected in May 2025
Last patient in the U.S. in the ongoing NCX 470 Denali Phase 3 trial has also completed their last visit and results remain on track for Q3 2025
March 19, 2025 –

Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update

Mon, 03 Mar 2025 01:30:00 -0400

Press Release
Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update

More patients on NCX 470 achieve an intraocular pressure (IOP) of less than or equal to 18 mmHg compared to latanoprost
New analysis provides additional data demonstrating differentiation of NCX 470
Development activities on track for U.S. New

Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update

Mon, 03 Mar 2025 01:30:00 -0400

Press Release
Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update

More patients on NCX 470 achieve an intraocular pressure (IOP) of less than or equal to 18 mmHg compared to latanoprost
New analysis provides additional data demonstrating differentiation of NCX 470
Development activities on track for U.S. New

Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update

Mon, 03 Mar 2025 01:30:00 -0400

Press Release
Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update

More patients on NCX 470 achieve an intraocular pressure (IOP) of less than or equal to 18 mmHg compared to latanoprost
New analysis provides additional data demonstrating differentiation of NCX 470
Development activities on track for U.S. New

Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update

Mon, 03 Mar 2025 01:30:00 -0400

Press Release
Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update

More patients on NCX 470 achieve an intraocular pressure (IOP) of less than or equal to 18 mmHg compared to latanoprost
New analysis provides additional data demonstrating differentiation of NCX 470
Development activities on track for U.S. New

Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream

Wed, 04 Dec 2024 01:30:00 -0400

Press Release
Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream

First commercialized product from the Nicox-Ocumension collaboration
Recent acquisitions have enhanced OcuMension's leadership in the ophthalmology field in the China market
Product made available quickly after approval thanks to a rapid

Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream

Wed, 04 Dec 2024 01:30:00 -0400

Press Release
Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream

First commercialized product from the Nicox-Ocumension collaboration
Recent acquisitions have enhanced OcuMension's leadership in the ophthalmology field in the China market
Product made available quickly after approval thanks to a rapid

Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream

Wed, 04 Dec 2024 01:30:00 -0400

Press Release
Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream

First commercialized product from the Nicox-Ocumension collaboration
Recent acquisitions have enhanced OcuMension's leadership in the ophthalmology field in the China market
Product made available quickly after approval thanks to a rapid

Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream

Wed, 04 Dec 2024 01:30:00 -0400

Press Release
Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream

First commercialized product from the Nicox-Ocumension collaboration
Recent acquisitions have enhanced OcuMension's leadership in the ophthalmology field in the China market
Product made available quickly after approval thanks to a rapid

Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results

Thu, 17 Oct 2024 01:30:00 -0400

Press Release
Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results

Topline results from the NCX 470 (bimatoprost grenod) Phase 3 Denali clinical trial expected in Q3 2025
Cash of €19.7 million on September 30, 2024, including the estimated net proceeds of the VYZULTA royalty sale and equity investment announced

Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results

Thu, 17 Oct 2024 01:30:00 -0400

Press Release
Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results

Topline results from the NCX 470 (bimatoprost grenod) Phase 3 Denali clinical trial expected in Q3 2025
Cash of €19.7 million on September 30, 2024, including the estimated net proceeds of the VYZULTA royalty sale and equity investment announced

StreetInsider.com News Articles

Nicox Provides Full Year 2025 Financial Results and Corporate Update

Nicox Provides Full Year 2025 Financial Results and Corporate Update

Nicox Provides Full Year 2025 Financial Results and Corporate Update

Nicox Provides Full Year 2025 Financial Results and Corporate Update

Nicox Announces Shareholder Q&A Webpage Available

Nicox Announces Shareholder Q&A Webpage Available

Nicox Announces Shareholder Q&A Webpage Available

Nicox Announces Shareholder Q&A Webpage Available

Counter tariff ideas in Broadcast TV- Benchmark

Counter tariff ideas in Broadcast TV- Benchmark

Counter tariff ideas in Broadcast TV- Benchmark

Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial

Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial

Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial

Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial

Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update

Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update

Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update

Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update

Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream

Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream

Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream

Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream

Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results

Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results